Plant Name: Penstemon linarioides
Taxonomic Information:
Plant ID: NPO16764
Plant Latin Name: Penstemon linarioides
Taxonomy Genus: Penstemon
Taxonomy Family: Plantaginaceae
Plant External Links:
NCBI TaxonomyDB:
265148
Plant-of-the-World-Online:
n.a.
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| ADRA2C; ADRA2A; | |
| NMUR2; | |
| GAA; ACHE; | |
| MAPK1; PRKCA; | |
| POLB; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Peptide receptor (family A GPCR) | NMUR2 | Neuromedin-U receptor 2 | Q9GZQ4 | CHEMBL1075144 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | PRKCA | Protein kinase C alpha | P17252 | CHEMBL299 |
| Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
| Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0009987; cellular process | GO:0030168; platelet activation | 6.848E-08 | 1.491E-03 | ADRA2A, ADRA2C, MAPK1, PRKCA |
| BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 9.002E-07 | 3.267E-03 | ADRA2A, ADRA2C |
| BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 9.002E-07 | 3.267E-03 | ADRA2A, ADRA2C |
| MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 4.502E-07 | 3.267E-03 | ADRA2A, ADRA2C |
| BP | GO:0032501; multicellular organismal process | GO:0006940; regulation of smooth muscle contraction | 2.012E-06 | 4.382E-03 | ADRA2A, ADRA2C, NMUR2 |
| BP | GO:0009987; cellular process | GO:0010700; negative regulation of norepinephrine secretion | 4.198E-06 | 7.031E-03 | ADRA2A, ADRA2C |
| MF | GO:0005488; binding | GO:0051379; epinephrine binding | 4.198E-06 | 7.031E-03 | ADRA2A, ADRA2C |
| BP | GO:0051179; localization | GO:0051223; regulation of protein transport | 5.500E-06 | 8.554E-03 | ACHE, ADRA2A, ADRA2C, MAPK1, PRKCA |
| BP | GO:0009987; cellular process | GO:0035556; intracellular signal transduction | 5.981E-06 | 8.682E-03 | ADRA2A, ADRA2C, MAPK1, NMUR2, POLB, PRKCA |
| CC | GO:0016020; membrane | GO:0005886; plasma membrane | 2.038E-04 | 7.157E-02 | ACHE, ADRA2A, ADRA2C, GAA, MAPK1, NMUR2, PRKCA |
| CC | GO:0044464; cell part | GO:0030424; axon | 4.683E-03 | 4.214E-01 | ADRA2C, MAPK1 |
| CC | Unclassified; | GO:0031143; pseudopodium | 7.020E-03 | 5.130E-01 | MAPK1 |
| CC | GO:0044464; cell part | GO:0032839; dendrite cytoplasm | 1.031E-02 | 6.618E-01 | MAPK1 |
| CC | GO:0044464; cell part | GO:0005737; cytoplasm | 1.433E-02 | 8.052E-01 | ADRA2A, ADRA2C, MAPK1, POLB, PRKCA |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09150 Organismal Systems | 09156 Nervous system | hsa04725 | Cholinergic synapse | 9.131E-06 | 1.050E-03 | ACHE, MAPK1, PRKCA |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04022 | cGMP-PKG signaling pathway | 3.105E-05 | 1.785E-03 | MAPK1, ADRA2C, ADRA2A |
| 09160 Human Diseases | 09161 Cancers | hsa05223 | Non-small cell lung cancer | 2.133E-04 | 3.291E-03 | MAPK1, PRKCA |
| 09150 Organismal Systems | 09155 Excretory system | hsa04960 | Aldosterone-regulated sodium reabsorption | 1.030E-04 | 3.291E-03 | MAPK1, PRKCA |
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 1.398E-04 | 3.291E-03 | NMUR2, ADRA2C, ADRA2A |
| 09160 Human Diseases | 09161 Cancers | hsa05214 | Glioma | 2.876E-04 | 3.291E-03 | MAPK1, PRKCA |
| 09150 Organismal Systems | 09156 Nervous system | hsa04730 | Long-term depression | 2.450E-04 | 3.291E-03 | MAPK1, PRKCA |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04150 | mTOR signaling pathway | 2.450E-04 | 3.291E-03 | MAPK1, PRKCA |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04370 | VEGF signaling pathway | 2.532E-04 | 3.291E-03 | MAPK1, PRKCA |
| 09150 Organismal Systems | 09151 Immune system | hsa04664 | Fc epsilon RI signaling pathway | 3.148E-04 | 3.291E-03 | MAPK1, PRKCA |
| 09150 Organismal Systems | 09156 Nervous system | hsa04720 | Long-term potentiation | 2.965E-04 | 3.291E-03 | MAPK1, PRKCA |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04012 | ErbB signaling pathway | 5.149E-04 | 3.947E-03 | MAPK1, PRKCA |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04912 | GnRH signaling pathway | 5.632E-04 | 3.947E-03 | MAPK1, PRKCA |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 6.932E-04 | 3.947E-03 | MAPK1, PRKCA |
| 09150 Organismal Systems | 09159 Environmental adaptation | hsa04713 | Circadian entrainment | 6.136E-04 | 3.947E-03 | MAPK1, PRKCA |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04540 | Gap junction | 5.268E-04 | 3.947E-03 | MAPK1, PRKCA |
| 09150 Organismal Systems | 09151 Immune system | hsa04666 | Fc gamma R-mediated phagocytosis | 5.881E-04 | 3.947E-03 | MAPK1, PRKCA |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04916 | Melanogenesis | 6.796E-04 | 3.947E-03 | MAPK1, PRKCA |
| 09160 Human Diseases | 09161 Cancers | hsa05231 | Choline metabolism in cancer | 6.932E-04 | 3.947E-03 | MAPK1, PRKCA |
| 09150 Organismal Systems | 09156 Nervous system | hsa04723 | Retrograde endocannabinoid signaling | 6.932E-04 | 3.947E-03 | MAPK1, PRKCA |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 7.207E-04 | 3.947E-03 | MAPK1, PRKCA |
| 09150 Organismal Systems | 09156 Nervous system | hsa04724 | Glutamatergic synapse | 8.818E-04 | 4.318E-03 | MAPK1, PRKCA |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 8.513E-04 | 4.318E-03 | MAPK1, PRKCA |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04919 | Thyroid hormone signaling pathway | 9.443E-04 | 4.318E-03 | MAPK1, PRKCA |
| 09150 Organismal Systems | 09153 Circulatory system | hsa04270 | Vascular smooth muscle contraction | 9.763E-04 | 4.318E-03 | MAPK1, PRKCA |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04071 | Sphingolipid signaling pathway | 9.763E-04 | 4.318E-03 | MAPK1, PRKCA |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05161 | Hepatitis B | 1.440E-03 | 5.670E-03 | MAPK1, PRKCA |
| 09150 Organismal Systems | 09151 Immune system | hsa04650 | Natural killer cell mediated cytotoxicity | 1.233E-03 | 5.252E-03 | MAPK1, PRKCA |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04072 | Phospholipase D signaling pathway | 1.401E-03 | 5.670E-03 | MAPK1, PRKCA |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04921 | Oxytocin signaling pathway | 1.683E-03 | 6.244E-03 | MAPK1, PRKCA |
| 09150 Organismal Systems | 09153 Circulatory system | hsa04261 | Adrenergic signaling in cardiomyocytes | 1.479E-03 | 5.670E-03 | MAPK1, PRKCA |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05164 | Influenza A | 2.059E-03 | 7.400E-03 | MAPK1, PRKCA |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 2.757E-03 | 9.236E-03 | MAPK1, PRKCA |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 2.731E-03 | 9.236E-03 | MAPK1, PRKCA |
| 09160 Human Diseases | 09161 Cancers | hsa05203 | Viral carcinogenesis | 2.811E-03 | 9.236E-03 | POLB, MAPK1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04015 | Rap1 signaling pathway | 2.975E-03 | 9.502E-03 | MAPK1, PRKCA |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| C00-D49: Neoplasms | Cancer | C00-C96 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
